Search

Long-distance migrants are constrained by widely separated hospitable habitats in geographically isolated locations, making them vulnerable to environmental change, both through natural and anthropogenic causes. Knowledge about their resource selection decisions is imperative to understand the drivers of their declines. The distinct periods within an annual cycle, when individuals experience different environmental circumstances, are inextricably linked through carry-over effects which can have important consequences for the individual, and consequently the population. In this study, we employ precise archival GPS-tracking data of European Nightjars (Caprimulgus europaeus) and high-resolution global land cover data to examine habitat selection during the sedentary wintering and breeding periods, as well as during autumn and spring migration, using a correlational approach. We demonstrate how nightjars use general habitat characteristics, such as landscape diversity, for high-order habitat selection, while resource selection at a finer spatial scale is reliant on fine-scale variables related to a habitat’s suitability, such as surface area of grassland and shrubland. We show that nightjars favour spatially diverse landscapes, which allows them to minimize time spent searching for optimal habitats. The considerable variation in the drivers of habitat selection between and within seasons shows how anthropogenic land-use change can have an array of different impacts on migrants by influencing large- and fine-scale habitat selection. This study shows the advantages of an individual based GPS-tracking approach, combined with high spatial resolution remote sensing data, and highlights the need for full annual-cycle research on scale dependent habitat selection of long-distance avian migrants.

Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of IL-13 with IL-13Rα1 and subsequent signaling. Similarly, tralokinumab-bound IL-13 cannot bind to IL-13Rα2, a proposed decoy receptor that is reported to bind IL-13 with extraordinarily high affinity. It has however not been fully elucidated to what extent tralokinumab interferes with the endogenous regulation of IL-13 through IL-13Rα2. In this mechanistic study, we used biophysical, biochemical, and cellular assays to investigate the effect of tralokinumab on the interaction between IL-13 and IL-13Rα1 and IL-13Rα2, respectively, as well as the effects on IL-13Rα2–mediated IL-13 internalization. We demonstrate that IL-13Rα2 binds IL-13 with exceptionally high affinity and that tralokinumab is unable to displace IL-13 from IL-13Rα2. In contrast to this, tralokinumab is able to disrupt the IL-13/IL-13Rα1 and IL-13Rα1/IL-13/IL-4Rα complex. Furthermore, we demonstrate that whereas the IL-13/tralokinumab complex is unable to bind IL-13Rα2, any IL-13 that is not bound by tralokinumab (i.e., free IL-13) can be bound by IL-13Rα2 and subsequently internalized, regardless of the presence of tralokinumab. In summary, our study indicates that tralokinumab does not interfere with endogenous IL-13Rα2–mediated regulation of free IL-13.